% | $
Quotes you view appear here for quick access.

Albany Molecular Research Inc. Message Board

  • yummyrutabaga yummyrutabaga Mar 3, 2006 10:11 PM Flag

    Certain Forward Looking Excuses

    Has anyone ever seen a longer list of certain forward looking statements at the end of an earnings release? Oddly, there's no mention of the potential impact of their purported nanotechnology (as described by numerous posts here on this msg. board) turning into picoearnings.

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the company's estimates of contract revenue for the first quarter of 2006 and for the full year 2006, statements made by the company's chief executive officer and chief financial officer, statements regarding the company's real property tax credit, the company's overseas operations, the license agreement with Bristol-Myers Squibb Company, the strength of the company's business, the patent infringement case related to Allegra and management's initiatives to sustain the company's momentum and long-term growth. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, the existence of deficiencies and/or material weaknesses in the company's internal controls over financial reporting, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, including continued softness in these markets, sales of Allegra and the company's receipt of significant royalties from the Allegra license agreement, the risk that Allegra may be approved for over-the-counter use, the over-the-counter sale of Claritin, the over-the-counter sale of generic alternatives for the treatment of allergies and the risk of new product introductions for the treatment of allergies including generic forms of Allegra, the success of the company's collaboration with Bristol-Myers Squibb Company related to biogenic amine reuptake inhibitors, the company's ability to enforce its intellectual property and technology rights, the company's ability to successfully develop novel compounds and lead candidates in its collaborative arrangements, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, including the possibility that the company's proposed acquisition of ComGenex will not close, that the closing may be delayed or that the companies may be required to modify aspects of the acquisition to close the acquisition, the satisfaction of closing conditions to the acquisition, the reaction of customers of the company and ComGenex to the acquisition, the company's timing and ability to successfully integrate ComGenex' operations (including migration of ComGenex to the company's systems and controls) and employees, the introduction of new services by competitors or the entry of new competitors into the markets for the company's and ComGenex' services, the failure by the company to retain key employees of ComGenex, failure to further develop and successfully market ComGenex' service offerings, failure to achieve anticipated revenues and earnings, costs related to the acquisition and any goodwill impairment related to such investments and acquisitions, the risks posed by international operations to the company, and the company's ability to effectively manage its growth, as well as those discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2004 as filed with the Securities and Exchange Commission on March 16, 2005,...

14.97-0.23(-1.51%)May 3 4:00 PMEDT